Plaque Psoriasis

Interchangeability Study Initiated for Adalimumab Biosimilar

Interchangeability Study Initiated for Adalimumab Biosimilar

By

Boehringer Ingelheim has initiated a clinical study to investigate the interchangeability between an adalimumab biosimilar candidate and Humira.

Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab

Treatment-Resistant Psoriatic Arthritis Improved by Ixekizumab

Ixekizumab benefits patients with treatment-resistant psoriatic arthritis when administered over a 2- or 4-week period.

Remicade Biosimilar FDA-Approved

Remicade Biosimilar FDA-Approved

By

The FDA has approved Renflexis, the second approved biosimilar to Remicade.

Sign Up for Free e-Newsletters